Display options
Share it on

Self Nonself. 2010 Jul;1(3):250-254. doi: 10.4161/self.1.3.12330. Epub 2010 Jan 05.

Glycosylation: An intrinsic sign of "danger".

Self/nonself

Jacob Rachmilewitz

Affiliations

  1. Goldyne Savad Institute of Gene Therapy; Hadassah-Hebrew University Medical Center; Jerusalem, Israel.

PMID: 21487481 PMCID: PMC3047787 DOI: 10.4161/self.1.3.12330

Abstract

The "danger" model of immunity posits that the immune system is triggered by endogenous danger signals, rather than exogenous non-self signals per se. It has been proposed that danger signals may consist of both intracellular "pre-packed" molecules released from damaged cells and stress-induced proteins. Here we focus on glycosylation aberrancies as a unifying concept for danger signaling. According to this proposition glycosylation patterns reliably reflect cellular phenotypic state and appearance of altered carbohydrate structures may constitute a pivotal phenotypic alteration that alarms the immune system to danger and initiates immunity. Viewed from this vantage point, healthy cells avert immune recognition by virtue of their normal terminal glycosylation patterns. By contrast, abnormal cells display and release glycoproteins and glycolipids with aberrant terminal glycosylation trees, which in turn immunologically flag these cells. Diverse carbohydrate-binding receptors are expressed on immune cells and are used to detect these phenotypic changes. Thus, in addition to the "pre-packed" and stress-induced signals this glycosylation-based signal represents an endogenous signal reliably reflecting the cell phenotypic status, enabling the immune system to monitor the tissue/cell's physical condition and to respond accordingly.

References

  1. Trends Immunol. 2005 Feb;26(2):104-10 - PubMed
  2. Biotechnol Bioeng. 2000 May 20;68(4):370-80 - PubMed
  3. Annu Rev Immunol. 1994;12:991-1045 - PubMed
  4. Semin Immunol. 1998 Oct;10(5):399-415 - PubMed
  5. Trends Immunol. 2001 Jun;22(6):337-42 - PubMed
  6. Nat Immunol. 2008 Jun;9(6):593-601 - PubMed
  7. Biotechnol Appl Biochem. 2002 Oct;36(2):133-40 - PubMed
  8. Nat Rev Mol Cell Biol. 2004 Feb;5(2):121-32 - PubMed
  9. Curr Opin Chem Biol. 2009 Dec;13(5-6):601-7 - PubMed
  10. Mol Hum Reprod. 1997 Jan;3(1):5-13 - PubMed
  11. Cancer Res. 2003 Nov 1;63(21):7284-90 - PubMed
  12. J Biol Chem. 1995 Nov 10;270(45):26970-5 - PubMed
  13. Eur J Biochem. 2000 Aug;267(15):4753-62 - PubMed
  14. Biotechnol Appl Biochem. 1995 Feb;21(1):87-100 - PubMed
  15. Nat Rev Immunol. 2008 Nov;8(11):874-87 - PubMed
  16. J Immunol. 1992 Jun 1;148(11):3679-85 - PubMed
  17. Trends Immunol. 2002 Jun;23(6):313-20 - PubMed
  18. Immunity. 2007 Aug;27(2):308-20 - PubMed
  19. J Biol Chem. 1993 Jan 5;268(1):385-91 - PubMed
  20. Biochem J. 1990 Dec 1;272(2):333-7 - PubMed
  21. Curr Opin Pharmacol. 2005 Aug;5(4):431-7 - PubMed
  22. J Cell Physiol. 2009 Jul;220(1):144-54 - PubMed
  23. Biotechnol Bioeng. 1998 Dec 5;60(5):596-607 - PubMed
  24. Essays Biochem. 1995;30:59-75 - PubMed
  25. Clin Chem. 2010 Feb;56(2):223-36 - PubMed
  26. Biotechnol Prog. 2000 Sep-Oct;16(5):751-9 - PubMed

Publication Types